{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T17:55:33Z","timestamp":1782496533399,"version":"3.54.5"},"reference-count":33,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"unspecified","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013342","name":"NIHR Imperial Biomedical Research Centre","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/501100013342","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Rigel","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,12,18]]},"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To determine the safety and efficacy of ruxolitinib (RUX) and fostamatinib (FOS) compared with standard of care (SOC) in patients requiring hospital admission for the treatment of COVID-19 pneumonia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Adaptive multiarm, multistage, randomised, open-label trial (three arm, two stage).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Five hospitals in England between October 2020 and September 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Hospitalised patients (\u226518 years) with COVID-19 pneumonia defined by a modified WHO COVID-19 severity grade of 3 or 4.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Participants were randomly assigned 1:1:1 to receive RUX (10 mg two times per day for 7 days then 5 mg two times per day for 7 days), FOS (150 mg two times per day for 7 days then 100 mg two times per day for 7 days) or SOC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measures<\/jats:title>\n                    <jats:p>Primary outcome was development of severe COVID-19 pneumonia (modified WHO severity grade\u22655) within 14 days of randomisation. Secondary outcomes included mortality, invasive and non-invasive ventilation, venous thromboembolism, duration of hospital stay, readmissions, inflammatory markers and serious adverse events (SAEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At stage 1, 181 patients were randomised, with 4 assessed as ineligible post randomisation. FOS was stopped early for futility with 16 participants (27.6%, n=58) developing severe COVID-19 pneumonia compared with 15 (25.0%, n=60) in the SOC arm (adjusted odds ratio (aOR) compared with SOC: 1.12; 95% CI 0.49 to 2.58; p=0.608). RUX progressed to stage 2 but the trial was stopped early due to slow recruitment. At the final analysis, 10 participants (16.1%, n=62) developed severe COVID-19 pneumonia in the RUX arm compared with 15 (24.6%, n=61) in the SOC arm (aOR: 0.63; 95%\u2009CI 0.25 to 1.57; p=0.161). Four (7.4%) participants in the FOS arm, none in the RUX arm and three (5.5%) in the SOC arm died within 14 days of randomisation. Infections were the most frequently reported SAE and were numerically higher in the FOS (10, 17.2%) and RUX (10, 16.1%) arms compared with SOC (7, 11.5%). Two unexpected serious adverse reactions occurred in the RUX arm only.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We found no evidence that FOS was superior to SOC for the treatment of COVID-19 pneumonia in patients requiring hospital admission. Due to early stopping, the trial was underpowered to establish RUX\u2019s effect in this population. Further study is needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04581954\">NCT04581954<\/jats:ext-link>\n                      ; EUDRA-CT:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-001750-22\/GB\">https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-001750-22\/GB<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-100583","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T13:51:16Z","timestamp":1770299476000},"page":"e100583","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic"],"prefix":"10.1136","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct04581954","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5962-0648","authenticated-orcid":false,"given":"Lorna","family":"Hazell","sequence":"first","affiliation":[{"name":"Imperial College Clinical Trials Unit, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clio","family":"Pillay","sequence":"additional","affiliation":[{"name":"Department of Immunology and Inflammation, Imperial College London, London, UK"},{"name":"Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Cornelius","sequence":"additional","affiliation":[{"name":"Imperial College Clinical Trials Unit, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Phillips","sequence":"additional","affiliation":[{"name":"Imperial College Clinical Trials Unit, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asad","family":"Charania","sequence":"additional","affiliation":[{"name":"Department of Immunology and Inflammation, Imperial College London, London, UK"},{"name":"Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4691-126X","authenticated-orcid":false,"given":"James","family":"Wason","sequence":"additional","affiliation":[{"name":"Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Cherlin","sequence":"additional","affiliation":[{"name":"Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinisa","family":"Savic","sequence":"additional","affiliation":[{"name":"Immunology, Leeds Teaching Hospitals NHS Trust, Leeds, UK"},{"name":"University of Leeds, Leeds, West Yorkshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Whittington","sequence":"additional","affiliation":[{"name":"Infectious Diseases and Acute Medicine, Northwick Park Hospital, Harrow, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratap","family":"Neelakantan","sequence":"additional","affiliation":[{"name":"Haemato-Oncology, Royal Berkshire NHS Foundation Trust, Reading, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Collini","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Cook","sequence":"additional","affiliation":[{"name":"Department of Immunology and Inflammation, Imperial College London, London, UK"},{"name":"Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Willicome","sequence":"additional","affiliation":[{"name":"Department of Immunology and Inflammation, Imperial College London, London, UK"},{"name":"Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragana","family":"Milojkovic","sequence":"additional","affiliation":[{"name":"Department of Immunology and Inflammation, Imperial College London, London, UK"},{"name":"Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2647-4688","authenticated-orcid":false,"given":"Onn Min","family":"Kon","sequence":"additional","affiliation":[{"name":"Respiratory Medicine, Imperial College Healthcare NHS Trust, London, London, UK"},{"name":"National Heart and Lung Institute, Imperial College London, London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taryn","family":"Youngstein","sequence":"additional","affiliation":[{"name":"Imperial College Healthcare NHS Trust, London, UK"},{"name":"National Heart and Lung Institute, Imperial College London, London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Innes","sequence":"additional","affiliation":[{"name":"Department of Immunology and Inflammation, Imperial College London, London, UK"},{"name":"Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Thursz","sequence":"additional","affiliation":[{"name":"Imperial College Healthcare NHS Trust, London, UK"},{"name":"Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham S","family":"Cooke","sequence":"additional","affiliation":[{"name":"Imperial College Healthcare NHS Trust, London, UK"},{"name":"Department of Infectious Diseases, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Vergis","sequence":"additional","affiliation":[{"name":"Department of Immunology and Inflammation, Imperial College London, London, UK"},{"name":"Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nichola","family":"Cooper","sequence":"additional","affiliation":[{"name":"Department of Immunology and Inflammation, Imperial College London, London, UK"},{"name":"Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"2026062610404488000_16.2.e100583.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30183-5"},{"key":"2026062610404488000_16.2.e100583.2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-020-05991-x"},{"key":"2026062610404488000_16.2.e100583.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2020.03.012"},{"key":"2026062610404488000_16.2.e100583.4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03451.x"},{"key":"2026062610404488000_16.2.e100583.5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2011.04470.x"},{"key":"2026062610404488000_16.2.e100583.6","unstructured":"Novartis . Jakavi 10mg tablets. 2022. Available: https:\/\/www.medicines.org.uk\/emc\/product\/7786\/smpc#gref"},{"key":"2026062610404488000_16.2.e100583.7","unstructured":"Grifols UK Ltd . Tavlesse 100 mg film-coated tablets 2023. Available: https:\/\/www.medicines.org.uk\/emc\/product\/11479\/smpc#gref [Accessed 7 Aug 2024]."},{"key":"2026062610404488000_16.2.e100583.8","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.2.5402.177","article-title":"HUMAN EXPERIMENTATION. CODE OF ETHICS OF THE WORLD MEDICAL ASSOCIATION. DECLARATION OF HELSINKI","volume":"2","author":"RICKHAM","year":"1964","journal-title":"Br Med J"},{"key":"2026062610404488000_16.2.e100583.9","doi-asserted-by":"crossref","unstructured":"World Health Organisation . COVID-19 Therapeutic Trial Synopsis. Geneva Switzerland: World Health Organisation, 2020.","DOI":"10.4324\/9781003120254-3"},{"key":"2026062610404488000_16.2.e100583.10","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-021-05190-z","article-title":"Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial","volume":"22","author":"Vergis","year":"2021","journal-title":"Trials"},{"key":"2026062610404488000_16.2.e100583.11","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"key":"2026062610404488000_16.2.e100583.12","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4067"},{"key":"2026062610404488000_16.2.e100583.13","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jclinepi.2017.11.011","article-title":"Instrumental variable methods for a binary outcome were used to informatively address noncompliance in a randomized trial in surgery","volume":"96","author":"Cook","year":"2018","journal-title":"J Clin Epidemiol"},{"key":"2026062610404488000_16.2.e100583.14","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2023.307230"},{"key":"2026062610404488000_16.2.e100583.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.05.019"},{"key":"2026062610404488000_16.2.e100583.16","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(22)00044-3"},{"key":"2026062610404488000_16.2.e100583.17","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000005682"},{"key":"2026062610404488000_16.2.e100583.18","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017007526"},{"key":"2026062610404488000_16.2.e100583.19","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2101643"},{"key":"2026062610404488000_16.2.e100583.20","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2031994"},{"key":"2026062610404488000_16.2.e100583.21","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101489","article-title":"Baricitinib in hospitalised patients with COVID-19: A meta-analysis of randomised controlled trials","volume":"49","author":"Selvaraj","year":"2022","journal-title":"EClinicalMedicine"},{"key":"2026062610404488000_16.2.e100583.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01109-6"},{"key":"2026062610404488000_16.2.e100583.23","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","article-title":"Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial","volume":"9","author":"Marconi","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2026062610404488000_16.2.e100583.24","unstructured":"US Food and Drug Administration . Letter of authorization: eua for baricitinib (olumiant) for treatment of coronavirus disease 2019. 2022. Available: https:\/\/www.fda.gov\/media\/143822\/download [Accessed 23 Dec 2024]."},{"key":"2026062610404488000_16.2.e100583.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00676-0"},{"key":"2026062610404488000_16.2.e100583.26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.intimp.2018.12.062","article-title":"Inhibition of spleen tyrosine kinase signaling protects against acute lung injury through blockade of NADPH oxidase and IL-17A in neutrophils and \u03b3\u03b4 T cells respectively in mice","volume":"68","author":"Nadeem","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"2026062610404488000_16.2.e100583.27","doi-asserted-by":"crossref","unstructured":"Alimova M , Sidhom E-H , Satyam A . A High Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury During the COVID-19 Pandemic. bioRxiv 2020;2020. doi:10.2139\/ssrn.3650600","DOI":"10.2139\/ssrn.3650600"},{"key":"2026062610404488000_16.2.e100583.28","doi-asserted-by":"crossref","first-page":"e491","DOI":"10.1093\/cid\/ciab732","article-title":"Fostamatinib for the Treatment of Hospitalized Adults With Coronavirus Disease 2019: A Randomized Trial","volume":"75","author":"Strich","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026062610404488000_16.2.e100583.29","doi-asserted-by":"crossref","unstructured":"Gotur DB , Malik A , Markovtsov V , et al . 88. Fostamatinib for the Treatment of Hospitalized Patients With COVID-19 Who Required Oxygen Supplementation: Results of a Phase 3 Trial. Open Forum Infect Dis 2023;10. doi:10.1093\/ofid\/ofad500.004","DOI":"10.1093\/ofid\/ofad500.004"},{"key":"2026062610404488000_16.2.e100583.30","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01979-w"},{"key":"2026062610404488000_16.2.e100583.31","doi-asserted-by":"crossref","first-page":"103629","DOI":"10.1016\/j.ebiom.2021.103629","article-title":"Host genetic factors determining COVID-19 susceptibility and severity","volume":"72","author":"Velavan","year":"2021","journal-title":"EBioMedicine"},{"key":"2026062610404488000_16.2.e100583.32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0274289","article-title":"Distorted TCR repertoires define multisystem inflammatory syndrome in children","volume":"17","author":"Malik","year":"2022","journal-title":"PLoS One"},{"key":"2026062610404488000_16.2.e100583.33","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1007\/s00134-020-06028-z","article-title":"Correction to: Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China","volume":"46","author":"Ruan","year":"2020","journal-title":"Intensive Care Med"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-100583","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T17:42:02Z","timestamp":1782495722000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-100583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,5]]},"published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1136\/bmjopen-2025-100583"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-100583","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}